Researchers Hope to Harness AI to Understand, Predict Response to ICIs
Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.
Diagnosis & Disease Information
Immunotherapy May Increase Risk for Hospitalization, Severe Respiratory Illness From COVID-19
Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.
Could Checkpoint Blockade Be Useful in Non-Hodgkin Lymphoma After All?
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
Bodyweight-Based Dosing of Nivolumab Results in Wastage
A review of practices prior to a change in nivolumab dosing demonstrated that bodyweight dosing resulted in a 6.1% rate of wastage at a significant cost compared with a fixed dose of 240 mg per dose.
Melanoma Risk and Biologic Therapy: Is There a Link?
Because the TNF-α pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.
Immune-Related Cutaneous Adverse Events Common In Skin Of Color Patients
Results of a single-center retrospective study revealed that patients with darker pigmented skin frequently experienced irCAEs, therefore, increased surveillance is needed in SOC patients.
Immune-Oncology Education Improved Patient Self-Efficacy
A patient education and monitoring program improved patients’ ability to manage and report adverse events related to treatment with ICIs.
Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Adding avelumab to best supportive care following chemo in advanced UC significantly improved OS compared with best supportive care alone.
Prior Chemotherapy Associated With Increased Risk of Death in Patients With Thoracic Cancer and COVID-19
Results of TERAVOLT showed that chemotherapy alone or in combination was significantly associated with increased risk of death for those with thoracic cancer and COVID-19.
- Loading...
Loading...
Loading... 
Loading...